BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

14 Apr 2024 5:45 p.m. 6:45 p.m.
WCN24-AB-2099, Poster Board= SUN-071
Hiddo Lambers Heerspink Poster Presenter